Phase 1 study of META 10-19, an IL-10-expressing, anti-CD19 CAR T cell product in patients with high-risk DLBCL.

作者
Qi Xu,Chongling Liu,Min Gao,M T Wu,Lei Xue,Youjia Li,Qian Chen,Jingjing Ren,Karthik Sathiyanadan,HJ Xu,X W Hu,Hui Li,Yugang Guo,Li Tang,Xingbing Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 2552-2552
标识
DOI:10.1200/jco.2026.44.16_suppl.2552
摘要

2552 Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of B cell lymphoma. However, limited duration of remission remains a significant challenge. We designed a metabolically armored anti-CD19 CAR T-cell product (META 10-19) that autocrine interleukin (IL)-10 to enhance antitumor activity, and assess the therapeutic potential in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Methods: This phase 1 study is designed to evaluate the safety and preliminary efficacy of META 10-19 in relapsed/refractory DLBCL patients aged 3–70 years old. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded by ASTCT criteria, and other adverse events (AEs) were evaluated according to CTCAE 5.0. Tumor response was assessed by investigators using Lugano 2014 criteria and IPCG criteria. Results: From December 2022 to December 2024, 14 patients with a median age of 54.5 years have been enrolled and received META 10-19 infusion at doses ranging from (0.002–0.1) ×10 6 cells/kg, following a standard lymphodepletion regimen (30 mg/m 2 /day Flu ×3 days, 300 mg/m 2 /day Cy ×3 days). All patients had relapsed/refractory disease, with high-risk features including primary refractory (n = 9), nodal and extranodal involvement (n = 6), CNS lymphoma (n = 5), and bulky disease (n = 2). The most frequent Grade 3–4 AEs comprised neutropenia (100%, 14/14), thrombocytopenia (85.7%, 12/14), and anemia (71.4%, 10/14). CRS was predominantly manifesting as low-grade events (Grade 1–2, n = 13; Grade 3, n = 1). ICANS developed in 2 patients (14.3%) with primary CNS disease, manifesting as transient seizures and classified as Grade 3. At 3 months post-infusion, the overall response rate was 100%, including 13 patients (92.9%) achieved complete response (CR), and 1 patient achieved partial response. As of December 1, 2025, with a median follow-up of 23.3 months (range, 5.6–33.4), 9 patients maintained CR for over 1 year, 4 for over 2 years, and the earliest infused patient remains in remission at 33.4 months. The median progression-free survival (PFS) and overall survival (OS) have not yet been reached, while the 12-month PFS rate and 12-month OS rate were 71.4% and 92.9% , respectively. Conclusions: This first-in-human trial of META 10-19, an IL-10 expressing, anti-CD19 CAR T-cell product, for the treatment of relapsed/refractory DLBCL has exhibited manageable safety profile and durable efficacy at ultra-low doses in patients with high-risk features. Studies evaluating larger cohorts and longer follow-up are ongoing. Clinical trial information: NCT05715606 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
共享精神的应助被wyc采纳,获得10
1秒前
hermit的应助被jisooya采纳,获得50
1秒前
1秒前
我是老大的应助被宿宿采纳,获得10
3秒前
4秒前
5秒前
予安完成签到,获得积分20
5秒前
OK完成签到,获得积分10
5秒前
风吹麦浪的应助被胡萝卜卜采纳,获得10
6秒前
大个的应助被之予无为采纳,获得10
6秒前
科研通AI65的应助被zo采纳,获得10
6秒前
KIB_yu发布了新的文献求助10
7秒前
TaoJ的应助被坚定的采波采纳,获得10
7秒前
WTTPAXL发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
乐乐的应助被叫你吃布丁采纳,获得10
8秒前
小二郎的应助被小太阳采纳,获得10
9秒前
10秒前
10秒前
zuoshoubo发布了新的文献求助10
10秒前
10秒前
一个橡果发布了新的文献求助10
12秒前
自由土豆完成签到,获得积分10
12秒前
13秒前
wyc发布了新的文献求助10
14秒前
15秒前
FashionBoy的应助被开心快乐大王采纳,获得10
15秒前
15秒前
璐璇完成签到 ,获得积分10
17秒前
guofuyan完成签到 ,获得积分10
17秒前
17秒前
18秒前
molihuakai的应助被苗条梨愁采纳,获得10
18秒前
乐乐的应助被苗条梨愁采纳,获得10
18秒前
小蘑菇的应助被苗条梨愁采纳,获得10
18秒前
完美世界的应助被木染采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541